Trial Profile
Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients Harboring Mutations in the PDE6B Gene Leading to a Defect in PDE6B Expression
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs HORA-PDE6B (Primary)
- Indications Retinitis pigmentosa
- Focus Adverse reactions; First in man
- Sponsors Coave Therapeutics
- 01 Jun 2023 Planned End Date changed from 1 Dec 2026 to 1 Dec 2029.
- 01 Jun 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Dec 2029.
- 01 Jun 2023 Status changed from active, no longer recruiting to recruiting.